Safety and immunogenicity of aerosolised Ad5-nCoV, intramuscular Ad5-nCoV, or inactivated COVID-19 vaccine CoronaVac given as the second booster following three doses of CoronaVac: a multicentre, open-label, phase 4, randomised trial
Rong Tang(Jiangsu Provincial Center for Disease Control and Prevention), Tao Zhu, Peng Wan(Academy of Military Medical Sciences), Hongxing Pan(Jiangsu Provincial Center for Disease Control and Prevention), Shipo Wu(Academy of Military Medical Sciences), Jin Zhong, Jin-Bo Gou, Fengjuan Shi(Jiangsu Provincial Center for Disease Control and Prevention), Hui Zheng(Southeast University), Lunbiao Cui(Jiangsu Provincial Center for Disease Control and Prevention), Jiahong Zhu, Fengcai Zhu(Jiangsu Provincial Center for Disease Control and Prevention), Busen Wang(Academy of Military Medical Sciences), Zhuo-Pei Li(Nanjing Medical University), Xiaolong Li(China Pharmaceutical University), Xue Wang(Ningxia Hui Autonomous Region Peoples Hospital), Yin Chen(Southern Medical University), Jingxian Liu(Jiangsu Provincial Center for Disease Control and Prevention), Xiaoyu Xu, Xiaoqin Chen(North Sichuan Medical University), Xiaoyin Zhang(Southeast University), Jingxin Li(Beijing Tongren Hospital), Lihua Hou(Academy of Military Medical Sciences), Xiling Guo(Jiangsu Provincial Center for Disease Control and Prevention), Zhizhou Song
Cited by 58
Related Papers
Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial
|The Lancet Infectious Diseases|2020|1.5k
Co-infection with respiratory pathogens among COVID-2019 cases
|Virus Research|2020|637
Serum Cytokine and Chemokine Profile in Relation to the Severity of Coronavirus Disease 2019 in China
|The Journal of Infectious Diseases|2020|391
A Family Cluster of Infections by a Newly Recognized Bunyavirus in Eastern China, 2007: Further Evidence of Person-to-Person Transmission
|Clinical Infectious Diseases|2011|268
An integrative drug repositioning framework discovered a potential therapeutic agent targeting COVID-19
|Signal Transduction and Targeted Therapy|2021|204